1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32255
Full metadata record
DC FieldValueLanguage
dc.contributor.authorReck, Martin-
dc.contributor.authorCiuleanu, Tudor-Eliade-
dc.contributor.authorCobo, Manuel-
dc.contributor.authorSchenker, Michael-
dc.contributor.authorZurawski, Bogdan-
dc.contributor.authorMenezes, Juliana-
dc.contributor.authorRichardet, Eduardo-
dc.contributor.authorBennouna, Jaafar-
dc.contributor.authorFelip, Enriqueta-
dc.contributor.authorJuan-Vidal, Oscar-
dc.contributor.authorAlexandru, Aurelia-
dc.contributor.authorCheng, Ying-
dc.contributor.authorSakai, Hiroshi-
dc.contributor.authorPaz-Ares, Luis-
dc.contributor.authorLu, Shun-
dc.contributor.authorJohn, Thomas-
dc.contributor.authorSun, Xiaowu-
dc.contributor.authorMoisei, Aniela-
dc.contributor.authorTaylor, Fiona-
dc.contributor.authorLawrance, Rachael-
dc.contributor.authorZhang, Xiaoqing-
dc.contributor.authorSylvester, Judi-
dc.contributor.authorYuan, Yong-
dc.contributor.authorBlum, Steven I-
dc.contributor.authorPenrod, John R-
dc.contributor.authorCarbone, David P-
dc.date2023-
dc.date.accessioned2023-03-08T01:06:33Z-
dc.date.available2023-03-08T01:06:33Z-
dc.date.issued2023-01-28-
dc.identifier.citationEuropean Journal of Cancer 2023; 183en_US
dc.identifier.issn1879-0852-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/32255-
dc.description.abstractIn CheckMate 9LA (NCT03215706), first-line nivolumab plus ipilimumab with chemotherapy (2 cycles) significantly improved overall survival versus chemotherapy (4 cycles) in patients with metastatic non-small cell lung cancer and no known sensitising epidermal growth factor receptor/anaplastic lymphoma kinase alterations. We present exploratory patient-reported outcomes (PROs; minimum follow-up, 2 years).en_US
dc.language.isoeng-
dc.subjectCTLA-4 inhibitoren_US
dc.subjectHealth-related quality of lifeen_US
dc.subjectImmune-checkpoint inhibitorsen_US
dc.subjectImmunotherapyen_US
dc.subjectNon-small cell lung canceren_US
dc.subjectPatient-reported outcomesen_US
dc.subjectProgrammed death (PD)-1 inhibitoren_US
dc.subjectSymptom burdenen_US
dc.titleFirst-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleEuropean Journal of Canceren_US
dc.identifier.affiliationDepartment of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany.en_US
dc.identifier.affiliationDepartment of Oncology, Institutul Oncologic Prof. Dr. Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain.en_US
dc.identifier.affiliationDepartment of Oncology, SF Nectarie Oncology Center, Craiova, Romania.en_US
dc.identifier.affiliationDepartment of Clinical Oncology, Ambulatorium Chemioterapii, Bydgoszcz, Poland.en_US
dc.identifier.affiliationDepartment of Oncology, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil.en_US
dc.identifier.affiliationDepartment of Clinical Oncology, Instituto Oncológico de Córdoba, Córdoba, Argentina.en_US
dc.identifier.affiliationDepartment of Thoracic Oncology, University Hospital of Nantes and INSERM, CRCINA, Nantes, France.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain.en_US
dc.identifier.affiliationDepartment of Oncology, Institute of Oncology Prof Dr Alexandru Trestioreanu Bucha, Bucharest, Romania.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Jilin Cancer Hospital, Changchun, China.en_US
dc.identifier.affiliationDepartment of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Clinical Research Unit, Universidad Complutense & CiberOnc, Madrid, Spain.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.en_US
dc.identifier.affiliationMedical Oncologyen_US
dc.identifier.affiliationAdelphi Values, Boston, MA, USA.en_US
dc.identifier.affiliationAdelphi Values, Adelphi Mill, Grimshaw Ln, Bollington, Cheshire, UK.en_US
dc.identifier.affiliationBristol Myers Squibb, Princeton, NJ, USA.en_US
dc.identifier.affiliationDepartment of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.en_US
dc.identifier.doi10.1016/j.ejca.2023.01.015en_US
dc.type.contentTexten_US
dc.identifier.pubmedid36871487-
dc.description.volume183-
dc.description.startpage174-
dc.description.endpage187-
local.name.researcherJohn, Thomas
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.languageiso639-1en-
item.cerifentitytypePublications-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

64
checked on Dec 21, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.